Martin Edwards Net Worth

The estimated Net Worth of Martin Edwards is at least $1.85 Million dollars as of 20 November 2023. Martin Edwards owns over 33,736 units of KalVista Pharmaceuticals Inc stock worth over $1,552,256 and over the last 5 years he sold KALV stock worth over $23,651. In addition, he makes $271,382 as Independent Chairman of the Board at KalVista Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Martin Edwards KALV stock SEC Form 4 insiders trading

Martin has made over 4 trades of the KalVista Pharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 33,736 units of KALV stock worth $62,074 on 20 November 2023.

The largest trade he's ever made was buying 33,736 units of KalVista Pharmaceuticals Inc stock on 20 November 2023 worth over $62,074. On average, Martin trades about 2,208 units every 37 days since 2019. As of 20 November 2023 he still owns at least 144,800 units of KalVista Pharmaceuticals Inc stock.

You can see the complete history of Martin Edwards stock trades at the bottom of the page.

Martin Edwards biography

Dr. Martin Edwards M.D. serves as Independent Chairman of the Board of the Company. He has served as a member of our Board since June 2019. Dr. Edwards is a Senior Partner (part time) at Novo Ventures, the venture capital arm of Novo A/S. Since 2003, Dr. Edwards has held various positions at Novo Holdings A/S, a life sciences investor. Earlier in his career, he was Corporate VP and Global Head of Drug Development for Novo Nordisk A/S, where he led pre-clinical and clinical drug development. Previously, Dr. Edwards was Chief Executive Officer of ReNeuron Ltd. and Chief Medical Officer/Vice President at Zymogenetics. He is currently the Chairman and a director of Vantia Ltd. and on the board of directors of Verona Pharma, Reata Pharmaceuticals Inc. and Inozyme Pharma Inc. Dr. Edwards was trained in physiology and medicine at the University of Manchester, where he obtained his M.D. He was elected a Member of the Royal College of Physicians, a Member with distinction of the Royal College of General Practitioners, a Fellow of the Faculty of Pharmaceutical Medicine and holds a MBA from the University of Warwick. In 2009, Dr. Edwards was made Adjunct Professor at CBS SIMI in Copenhagen. Edwards is qualified to serve on our Board because of his extensive experience and knowledge in the biotechnology industry.

What is the salary of Martin Edwards?

As the Independent Chairman of the Board of KalVista Pharmaceuticals Inc, the total compensation of Martin Edwards at KalVista Pharmaceuticals Inc is $271,382. There are 7 executives at KalVista Pharmaceuticals Inc getting paid more, with Thomas Crockett having the highest compensation of $1,731,160.

How old is Martin Edwards?

Martin Edwards is 64, he's been the Independent Chairman of the Board of KalVista Pharmaceuticals Inc since 2019. There are 2 older and 15 younger executives at KalVista Pharmaceuticals Inc. The oldest executive at KalVista Pharmaceuticals Inc is Arnold Oronsky, 80, who is the Independent Director.

What's Martin Edwards's mailing address?

Martin's mailing address filed with the SEC is C/O KALVISTA PHARMACEUTICALS, INC., 55 CAMBRIDGE PARKWAY, SUITE 901E, CAMBRIDGE, MA, 02142.

Insiders trading at KalVista Pharmaceuticals Inc

Over the last 8 years, insiders at KalVista Pharmaceuticals Inc have traded over $74,823,944 worth of KalVista Pharmaceuticals Inc stock and bought 4,877,063 units worth $58,591,487 . The most active insiders traders include Holdings A/S Novo, Capital Management, L.P.Ra ..., and Rajeev M. Shah. On average, KalVista Pharmaceuticals Inc executives and independent directors trade stock every 19 days with the average trade being worth of $835,088. The most recent stock trade was executed by Benjamin L Palleiko on 6 September 2024, trading 15,625 units of KALV stock currently worth $167,500.

What does KalVista Pharmaceuticals Inc do?

kalvista is a clinical stage pharmaceuticals company focused on the discovery, development, and commercialization of small molecule protease inhibitors.

Complete history of Martin Edwards stock trades at KalVista Pharmaceuticals Inc, Reata Pharmaceuticals Inc, Verona Pharma Plc, Morphic Inc, and Inozyme Pharma

KalVista Pharmaceuticals Inc executives and stock owners

KalVista Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Thomas Crockett,
  Chief Executive Officer, Director
• Edward Feener,
  Chief Scientific Officer
• Benjamin Palleiko,
  Chief Financial Officer, Chief Business Officer
• Thomas Andrew Crockett M.B.A.,
  CEO & Director
• Christopher Yea,
  Chief Development Officer
• Benjamin L. Palleiko,
  Chief Bus. Officer & CFO
• Dr. Christopher M. Yea Ph.D.,
  Chief Devel. Officer
• Martin Edwards,
  Independent Chairman of the Board
• Edward Unkart,
  Independent Director
• Arnold Oronsky,
  Independent Director
• Albert Cha,
  Independent Director
• Brian Pereira,
  Independent Director
• Daniel Soland,
  Independent Director
• Michael Smith,
  Senior Vice President - Development
• Andreas Maetzel,
  Senior Vice President - Medical
• Jarrod Aldom,
  VP of Corp. Communications
• John B. McKune,
  VP of Fin.
• Stephen Donnelly,
  Director of Fin. and Company Sec.
• Dr. Paul K. Audhya M.B.A., M.D.,
  Chief Medical Officer
• Dr. Michael D. Smith Pharm.D.,
  Sr. VP of Devel.
• Rachel Morten,
  Head of Regulatory Affairs and QA
• Leah Monteiro,
  Sr. Director of Corp. Communications & Investor Relations
• Dr. Edward P. Feener Ph.D.,
  Chief Scientific Officer
• Joshua Resnick,
  Director
• Iv, Llcsv Life Sciences Fun...,
  
• Capital Management, Llc Kol...,
  
• Capital Management, L.P.Ra ...,
  
• Rajeev M. Shah,
  Director
• Healthcare Capital Partners...,
  
• Holdings A/S Novo,
  10% owner
• William Fairey,
  
• Paul K. Audhya,
  CHIEF MEDICAL OFFICER
• Healthcare Capital Partners...,
  
• Nancy Stuart,
  Director
• Patrick Treanor,
  Director
• Brian Piekos,
  Chief Financial Officer
• Healthcare Capital Partners...,